Hypereosinophilia as a presenting sign of advanced pancreatic adenocarcinoma: a rare, severe presentation

BMJ Case Rep. 2023 Dec 26;16(12):e256235. doi: 10.1136/bcr-2023-256235.

Abstract

Pancreatic adenocarcinoma (PA) is the third most lethal malignancy worldwide with only a 7.7% 5-year survival rate. Prognosis is poor with more than 50% of patients presenting with stage IV disease. Despite focused attention on early detection and treatment, pathogenesis and early symptomatology are not well described. In addition to prodromal symptoms, hypereosinophilia has been identified as a marker of malignancy in both PA and other solid tumour and haematological malignancies. Peripheral hypereosinophilia (PH) secondary to solid organ tumours, however, is rare, with only four cases of PA reported to date. We present a case of advanced PA with associated severe PH in a man in his early 50s. Time from diagnosis to death in this patient was only 6 weeks, emphasising the need to consider malignancy in the differential diagnosis for a patient that presents with a severe PH of unknown origin.

Keywords: Gastroenterology; Haematology (incl blood transfusion); Pancreas and biliary tract; Pancreatic cancer.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma* / complications
  • Adenocarcinoma* / diagnosis
  • Humans
  • Male
  • Pancreatic Neoplasms* / complications
  • Pancreatic Neoplasms* / diagnosis
  • Pancreatic Neoplasms* / pathology
  • Prognosis